Cardiol Therapeutics - shares with blockbuster potential

Humanity is still caught up in the covid pandemic. The shares of vaccine manufacturers have skyrocketed. Despite great successes in combating the pandemic, there are also downsides. These are secondary damages, such as damage to the heart. This is where the Canadian company Cardiol Therapeutics comes in. The company is currently undergoing promising clinical trials with preparations based on cannabidiol that are intended to treat inflammatory heart disease. Recent research shows that cannabis ingredients can prevent infection with the Corona virus by blocking its entry into cells. This suggests that Cardiol's preparations could have blockbuster potential. Analysts unanimously believe that the shares, which are also listed on the NASDAQ, have the potential to multiply.

Den vollständigen Artikel lesen ...